Another TNBC case, PDXBC9, was associated with a high response to targeted therapies such as HSP90 and AURKA inhibitors, yet this tumor carried no known molecular alterations in the HSP90 or AURKA pathways. The gene discussed is AURKA; the disease is neoplasm.